In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sulzer Biologics Inc.

Division of Zimmer Biomet Holdings Inc.

Latest From Sulzer Biologics Inc.

After the Cage Rage

The long follow-up time in clinical trials and subjective endpoints of pain and quality of life continue to create market acceptance issues for new spinal surgery techniques. Cages are the latest example, as emerging long-term follow-up data bring into question their ability to enhance spinal fusion. Many believe artificial discs will eventually move orthopedics along the continuum from repair and restoration to replacement, but creating a physiologically active device capable of pumping water and waste, and determining which patients will benefit from it, is a formidable long-term challenge. In the meantime, minimally invasive spinal decompression procedures including vertebroplasty and kyphoplasty are gaining in popularity, as are, to some extent, radiofrequency techniques such as IDET. But here too, until multi-year follow-data from prospective trials are available, their use will also remain controversial.
Medical Device Innovation

Sulzer's New Brew

Orthopedic suppliers have tentatively explored the opportunity in biologics for years. Now, one leading suppliers, SulzerMedica, is launching a dedicated business designed to focus on the opportunity. For Sulzer, biologics represent a promising new technology that could revitalize an orthopedic business beset by pricing and commmoditization pressures. But biologics also will require Sulzer to manage its business differently than medical device companies historically have.
BioPharmaceutical Medical Device

When the Body Alone Can't Build Bone

Orthobiologics are now on the horizon, driving suppliers to increase R&D spending. The goal is to develop high-margin products that will actively promote bone formation. Has the slow progress to commercialization of the first two products--bone morphogenic proteins developed by the collaborations of Stryker Corp/Creative Biomolecules and Genetics Institute/Sofamor Danek--helped prime the market to accept a new technology? Or has the perception of delay dampened enthusiasm and scared off some of the big orthopedics players?
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Zimmer Biomet Holdings Inc.
  • Senior Management
  • Jerry Marlar, Pres.
    John Ranieri, PhD, VP, R&D
  • Contact Info
  • Sulzer Biologics Inc.
    Phone: (800) 888-4676
    9900 Spectrum Drive
    Austin, TX 78717